Global Patent Index - EP 2961483 A4

EP 2961483 A4 20170308 - METHODS AND COMPOSITIONS FOR ENHANCING AN IMMUNE RESPONSE, BLOCKING MONOCYTE MIGRATION, AMPLIFYING VACCINE IMMUNITY AND INHIBITING TUMOR GROWTH AND METASTASIS

Title (en)

METHODS AND COMPOSITIONS FOR ENHANCING AN IMMUNE RESPONSE, BLOCKING MONOCYTE MIGRATION, AMPLIFYING VACCINE IMMUNITY AND INHIBITING TUMOR GROWTH AND METASTASIS

Title (de)

VERFAHREN UND ZUSAMMENSETZUNGEN ZUR VERBESSERUNG EINER IMMUNREAKTION, ZUR BLOCKIERUNG EINER MONOZYTENMIGRATION, ZUR VERSTÄRKUNG EINER IMPFSTOFFIMMUNITÄT UND ZUR HEMMUNG VON TUMORWACHSTUM UND -METASTASEN

Title (fr)

PROCÉDÉS ET COMPOSITIONS PERMETTANT D'AMÉLIORER UNE RÉPONSE IMMUNITAIRE, DE BLOQUER LA MIGRATION DES MONOCYTES, D'AMPLIFIER L'IMMUNITÉ D'UN VACCIN ET D'INHIBER LA CROISSANCE D'UNE TUMEUR ET DES MÉTASTASES

Publication

EP 2961483 A4 20170308 (EN)

Application

EP 14756530 A 20140303

Priority

  • US 201361771738 P 20130301
  • US 201361771744 P 20130301
  • US 201361807189 P 20130401
  • US 201361818176 P 20130501
  • US 2014020018 W 20140303

Abstract (en)

[origin: WO2014134621A2] Provided are methods for enhancing an immune response, methods for decreasing monocyte recruitment to lymph nodes, and methods for amplifying vaccine immunity by administering to an individual various monocyte migration inhibitors alone or in combination, and optionally in conjunction with an antigen, vaccine, or anti-tumor preparation. The invention also provides related methods of inhibiting tumor growth and metastasis. In addition, related compositions comprising one or more monocyte migration inhibitors and optionally comprising antigens, vaccines, or anti-tumor preparations are provided, as are kits containing such compositions.

IPC 8 full level

A61P 31/12 (2006.01); A61K 31/404 (2006.01); A61K 31/41 (2006.01); A61K 31/437 (2006.01); A61K 31/505 (2006.01); A61K 31/537 (2006.01)

CPC (source: EP US)

A61K 31/404 (2013.01 - EP); A61K 31/41 (2013.01 - EP); A61K 31/4178 (2013.01 - EP); A61K 31/4184 (2013.01 - EP); A61K 31/437 (2013.01 - EP); A61K 31/505 (2013.01 - EP); A61K 31/537 (2013.01 - EP); A61K 39/0011 (2013.01 - EP US); A61K 39/39 (2013.01 - EP); A61K 45/06 (2013.01 - EP); A61P 31/12 (2018.01 - EP); A61K 2039/55511 (2013.01 - EP); A61K 2039/55555 (2013.01 - EP); A61K 2039/55561 (2013.01 - EP)

C-Set (source: EP)

  1. A61K 31/404 + A61K 2300/00
  2. A61K 31/4178 + A61K 2300/00
  3. A61K 31/4184 + A61K 2300/00
  4. A61K 31/41 + A61K 2300/00
  5. A61K 31/437 + A61K 2300/00
  6. A61K 31/505 + A61K 2300/00
  7. A61K 31/537 + A61K 2300/00

Citation (search report)

  • [XY] WO 2012068531 A2 20120524 - GEN HOSPITAL CORP [US], et al
  • [Y] CN 101612400 A 20091230 - ZHILONG CHEN
  • [XY] NOGUCHI R ET AL: "Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities", ONCOLOGY REPORTS, SPANDIDOS PUBLICATIONS, GR, vol. 22, no. 2, 1 August 2009 (2009-08-01), pages 355 - 360, XP002744523, ISSN: 1021-335X, [retrieved on 20090801], DOI: 10.3892/OR_00000445
  • [A] MICHIO KOSUGI ET AL: "Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer", HUMAN CELL, vol. 20, no. 1, 1 February 2007 (2007-02-01), UK; JP, pages 1 - 9, XP055290297, ISSN: 0914-7470, DOI: 10.1111/j.1749-0774.2007.00025.x
  • [A] AKIKO MIYAZAKI ET AL: "Anti-inflammatory effect of angiotensin type 1 receptor antagonist on endotoxin-induced uveitis in rats", GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY ; INCORPORATING GERMAN JOURNAL OF OPHTHALMOLOGY, SPRINGER, BERLIN, DE, vol. 246, no. 5, 18 December 2007 (2007-12-18), pages 747 - 757, XP019629681, ISSN: 1435-702X
  • [A] KAYO SAGAWA ET AL: "Angiotensin receptor blockers suppress antigen-specific T cell responses and ameliorate collagen-induced arthritis in mice", ARTHRITIS & RHEUMATISM, vol. 52, no. 6, 1 June 2005 (2005-06-01), pages 1920 - 1928, XP055156348, ISSN: 0004-3591, DOI: 10.1002/art.21040
  • [A] MAEDA A ET AL: "Immunosuppressive effect of angiotensin receptor blocker on stimulation of mice CTLs by angiotensin II", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 9, no. 10, 1 September 2009 (2009-09-01), pages 1183 - 1188, XP026502010, ISSN: 1567-5769, [retrieved on 20090621], DOI: 10.1016/J.INTIMP.2009.06.006

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2014134621 A2 20140904; WO 2014134621 A3 20141106; EP 2961483 A2 20160106; EP 2961483 A4 20170308

DOCDB simple family (application)

US 2014020018 W 20140303; EP 14756530 A 20140303